Esperion Therapeutics
ESPR
ESPR
156 hedge funds and large institutions have $1.2B invested in Esperion Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% less capital invested
Capital invested by funds: $1.25B → $1.2B (-$50.9M)
5.5% less ownership
Funds ownership: 105.51% → 100.01% (-5.5%)
52% less call options, than puts
Call options by funds: $46.4M | Put options by funds: $96.8M
Holders
156
Holding in Top 10
7
Calls
$46.4M
Puts
$96.8M
Top Buyers
| 1 | +$11.1M | |
| 2 | +$10.4M | |
| 3 | +$8.48M | |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$6.25M |
| 5 |
JPMorgan Chase & Co
New York
|
+$6.09M |
Top Sellers
| 1 | -$33.8M | |
| 2 | -$22.5M | |
| 3 | -$19.1M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$15.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$15.6M |